This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
VAV1 / Proto-oncogene vav · Western blot design guide
Design a Western Blot for VAV1
Real validated VAV1 Western blot protocols, expected-band and isoform facts, troubleshooting for weak or shifted signal, and recommended anti-VAV1 WB antibodies. Everything you need to plan the experiment before you commit precious samples.
Evidence assembled September 2026 · For research use; verify linked source records and product datasheet before use
VAV1 Western Blot Experimental Design Guide
Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | ~98.3 kDa | |
| Gel | 8–10% (standard starting point) | |
| Positive control | Bone marrow (IHC candidate; verify WB) +4 more | |
| Negative control | Adipose tissue (IHC candidate; verify WB) |
Important caveats
Reasons your observed band may differ from the expected size.
| PTM | Phosphorylated | |
| Caveat | Phosphorylation-state controls | |
| Gene-set association | MSigDB C7 membership | |
| Isoform | 2 isoform(s) |
Section 1
Real Curated VAV1 Western Blot Protocols
The A30436 protocol combines labelled catalog values with standard starting conditions. Published comparisons retain their own sample, reagent and detection scope.
| Sample / lysate | extracts from NIH-3T3 cells, (catalog A30436) |
| Gel % | 8–10% (standard starting point) |
| Load | 20–30 µg total protein per lane; optimize for abundance (standard starting point) |
| Transfer | Standard semi-dry transfer; verify efficiency (standard starting point) |
| Membrane | 0.45 µm PVDF (standard starting point) |
| Blocking | 5% milk or 5% BSA in TBST (standard starting point) |
| Primary antibody | A30436; use the WB datasheet starting dilution (standard starting point) |
| Primary incubation | Overnight at 4 °C (standard starting point) |
| Secondary antibody | 1:20000 (catalog A30436) |
| Secondary incubation | 1 h at room temperature (standard starting point) |
| Wash | 3 × 5 min in TBST (standard starting point) |
| Detection | ECL; bracket exposures to avoid saturation (standard starting point) |
Section 2
What Is the Expected VAV1 Western Blot Band Size?
VAV1 is predicted at 98.3 kDa; isoforms are documented, but their migration and any visible band shifts are not established.
| Band near 98.3 kDa | Consistent with the predicted VAV1 size; confirm identity with controls. |
| Several bands | Isoforms 1 and 2 are documented, but distinct migration is unproven. |
| Band above 98.3 kDa | Identity requires controls; the supplied features do not establish this shift. |
| Band below 98.3 kDa | Identity requires controls; no isoform mass is supplied. |
💡Expected VAV1 appearanceVAV1 has a predicted mass of 98.3 kDa, but no empirical band size is supplied; confirm any band near that position with antibody and sample controls.
| Predicted VAV1 mass | Sets a 98.3 kDa reference for the expected band. |
| Isoform 1 | Its individual mass and migration are not supplied. |
| Isoform 2 | Its individual mass and migration are not supplied. |
| Alternative splicing | Could change band size, but distinct resolvable bands are not established. |
| Situation | Likely cause | Next action |
|---|---|---|
| No band in lysate | VAV1 may be below detection in this sample. | Check sample loading and a positive control. |
| Band higher than expected | The supplied features do not establish the shift. | Confirm identity with an independent antibody or VAV1 depletion control. |
| Band lower than expected | An isoform is possible, but its mass is unknown. | Confirm identity with an independent antibody or VAV1 depletion control. |
| Multiple bands | Two isoforms are documented, but their migration is unknown. | Use band-identity controls before assigning either band. |
| Weak or no signal | VAV1 may be below assay detection. | Check loading, antibody performance, and a positive control. |
Experiment evidence
Western blot images showing VAV1 band
A30436 · VAV1
A00691-2 · VAV1
A00691-1 · VAV1
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for VAV1 Western blot
🧪HPA-IHC candidate guidance (verify in WB): For positive controls for VAV1 in Western blot, you can use bone marrow lysate, which HPA rates High for VAV1.
Positive control: Bone marrow (IHC candidate; verify WB)
Negative control: Adipose tissue (IHC candidate; verify WB)
Loading controls: Run GAPDH, β-actin, and a total-protein stain such as Ponceau alongside the samples.
⚠️Feasibility: HPA reports no VAV1 detection in adipose tissue, but confirm its lack of signal by Western blot.
HPA tissue expression evidence for VAV1
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Higher expression tissues · candidate positive controls from IHC
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Bone marrow | hematopoietic cells | High | Protein (IHC) | HPA → |
| Lymph node | non-germinal center cells | High | Protein (IHC) | HPA → |
| Tonsil | non-germinal center cells | High | Protein (IHC) | HPA → |
| Spleen | cells in red pulp | Medium | Protein (IHC) | HPA → |
| Testis | elongated or late spermatids | Medium | Protein (IHC) | HPA → |
Lower expression tissues · IHC evidence, not confirmed WB-negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | adipocytes | Not detected | Protein (IHC) | HPA → |
| Adrenal gland | glandular cells | Not detected | Protein (IHC) | HPA → |
| Breast | adipocytes | Not detected | Protein (IHC) | HPA → |
| Bronchus | respiratory epithelial cells | Not detected | Protein (IHC) | HPA → |
| Caudate | glial cells | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced VAV1 Western Blot Tips
Deeper troubleshooting and optimisation questions for VAV1, answered from its protein features.
How should VAV1 band migration be interpreted?
Band shift · Use the separately labelled calculated mass and catalog-observed evidence above. A sequence annotation does not establish an observed migration shift. Verify target identity with orthogonal controls.
Could VAV1 isoforms produce different bands?
Isoforms · UniProt lists isoforms 1 and 2. Isoform 2 lacks residues 187–218 of the canonical sequence, so it may migrate differently. Check whether the antibody recognizes a region retained in both isoforms before comparing bands.
Does VAV1 phosphorylation explain a band shift?
PTM · UniProt lists phosphotyrosine at positions 826 and 844. These features establish modification sites but do not demonstrate a visible shift or explain any difference from the predicted mass. Compare treated and matched control samples if assessing a shift.
The supplied UniProt sites are Tyr826 and Tyr844. Match the antibody’s stated site to the UniProt sequence; paper or antibody numbering may use a different convention. A site-specific signal should be interpreted separately from total VAV1.
The supplied UniProt features list no glycosylation sites, signal peptide, or propeptide. They therefore provide no basis for attributing an unexpected band to those features. Compare the band with the 98.3 kDa prediction and consider the listed isoforms.
The supplied UniProt sites are Tyr826 and Tyr844. Match the antibody’s stated site to the UniProt sequence; paper or antibody numbering may use a different convention. A site-specific signal should be interpreted separately from total VAV1.
The supplied UniProt features list no glycosylation sites, signal peptide, or propeptide. They therefore provide no basis for attributing an unexpected band to those features. Compare the band with the 98.3 kDa prediction and consider the listed isoforms.
Does this guide establish induction of VAV1?
Induction · No general induction response is established by this guide. A pathway or gene-set association is not evidence of induction in a particular specimen. Verify the relevant treatment and control in a target-specific experiment.
How should transfer be checked for VAV1?
Transfer · Standard workflow guidance: verify transfer efficiency for the intended target size before interpreting a weak signal. Use total-protein assessment and optimize transfer for the membrane, gel and apparatus; the labelled catalog values take precedence.
How should blocking be optimized?
Blocking · Standard workflow guidance: follow the A30436 datasheet where specified. Otherwise compare 5% milk or 5% BSA in TBST; for a phospho-specific assay start with BSA. Optimize background and specific signal with matched controls.
How should VAV1 bands be quantified across samples?
Quantitation · Use the same band definition across samples and distinguish total VAV1 from phosphosite-specific signal. If two bands appear, assess whether isoform 2’s missing residues 187–218 affect antibody recognition before combining their intensities.
What size should VAV1 appear on a Western blot?
Interpretation · The supplied predicted mass for VAV1 is 98.3 kDa. No empirical apparent band is provided, so use 98.3 kDa as a reference rather than an exact migration position.
Consider isoform 2, which lacks canonical residues 187–218, and check whether the antibody epitope lies in that segment. The supplied features do not establish the identity of an observed lower band.
Consider isoform 2, which lacks canonical residues 187–218, and check whether the antibody epitope lies in that segment. The supplied features do not establish the identity of an observed lower band.
Boster reagents
VAV1 Western Blot Antibodies
Catalog antibodies with Western blot application and product-specific WB images. Evaluate suitability with the reported sample, controls and experimental conditions.
Real WB data
Anti-Proto-oncogene vav VAV1 Antibody
Cat # A30436
Real WB data
Anti-VaV1 (A168) Antibody
Cat # A00691-2
Real WB data
Anti-Proto-oncogene vav VAV1 Antibody
Cat # A00691-1
Three the supplier anti-VAV1 antibodies list Human, Mouse, and Rat reactivity and have WB images. Supplied evidence is limited to product captions showing NIH-3T3 extracts for A30436 and A00691-1, and HeLa, Jurkat, mouse spleen, and rat spleen lysates for A00691-2.
Which to pick: Choose by the pictured sample context: A00691-2 shows HeLa, Jurkat, mouse spleen, and rat spleen lysates at 1:500 antibody dilution. A30436 and A00691-1 show NIH-3T3 extracts; their captions specify a 1:20000 secondary antibody dilution.
Source: BosterBio VAV1 gene-info card — filtered to Western-blot-capable antibodies; each card shows that product's actual WB validation figure.
References
- UniProt Consortium. UniProt entry P15498.
- Human Protein Atlas. VAV1 tissue expression.
- PMC7615736 — target-verified WB comparison
- PMC4048212 — target-verified WB comparison
- PMC3951479 — target-verified WB comparison